造血幹細胞移植 - 需要更進一步的研究與開發

造血幹細胞移植 - 需要更進一步的研究與開發 是由出版商Datamonitor在2009年04月所出版的。 這份英文市場調查報告書包含68 pages 價格從美金3800起跳。

簡介

目錄

Abstract

Introduction

Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes.

Scope of this research

• Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens
• Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends
• Unmet needs and research priorities in the field of HSCT
• Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Research and analysis highlights

The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.

The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.

The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.

Key reasons to purchase this research

• Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens
• Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
• Identify unmet needs and research priorities in the field of HSCT

Table of Contents

EXECUTIVE SUMMARY

• Scope of analysis
• Datamonitor insight into hematopoietic stem cell transplantation
• Contributing experts
• Related reports
• Upcoming reports

HEMATOPOIETIC STEM CELL TRANSPLANTATION OVERVIEW

• Definition
• Overview of the hematopoietic stem cell transplantation procedure
• Use and applications of hematopoietic stem cell transplantation
• Types of stem cell transplants
  • Stem cell donors
  • Stem cell sources
  • Conditioning

• Mortality and survival data

PHARMACOLOGIC USE

• Conditioning regimens
  • Myeloablative regimens
  • Reduced-intensity conditioning
  • Conditioning by type of hematologic malignancy
  • Research & development in the conditioning field

• Prophylaxis and treatment of hematopoietic stem cell transplantation complications
  • Early complications
  • Late complications

• Other areas of research & development
  • Augmentation of the graft-versus-tumor (GVT) effect
  • Expansion of allogeneic HSCT to solid tumors

UNMET NEEDS & RESEARCH PRIORITIES

• Key findings
• Unmet needs and research priorities in hematopoietic stem cell transplantation
  • HSCT remains an underutilized treatment
  • Relapse remains the main cause of death after HSCT
  • HSCT is in need of an overall refinement
  • The effective management of graft-versus-host disease is considered a priority

BIBLIOGRAPHY

APPENDIX

TABLES

• Table: Hematopoietic stem cell transplantation: definitions
• Table: Donor types for allogeneic hematopoietic stem cell transplantation
• Table: Comparison of stem cell sources for hematopoietic stem cell transplantation
• Table: Reduced-intensity conditioning (RIC) and nonmyeloablative regimens: mode of action
• Table: Three-year survival rates for patients with acute myeloid leukemia and diffuse large B-cell lymphoma
• Table: Examples of radiation-based conditioning regimens used in hematopoietic stem cell transplantation
• Table: Examples of chemotherapy-based conditioning regimens used in hematopoietic stem cell transplantation
• Table: Examples of reduced-intensity conditioning regimens used in hematopoietic stem cell transplantation
• Table: Examples of conditioning regimens used in hematopoietic stem cell transplantation by type of hematologic malignancy
• Table: Investigation of Rituxan and Campath in regimens used in hematopoietic stem cell transplantation conditioning
• Table: Investigation of anti-CD20 radioimmunotherapy in hematopoietic stem cell transplantation conditioning
• Table: Early complications of hematopoietic stem cell transplantation
• Table: Selected drugs available for use in the prophylaxis of acute graft-versus-host disease
• Table: Selected drugs investigated in the treatment of steroid-refractory acute graft-versus-host disease
• Table: Drugs/therapies in company-sponsored Phase III development for graft-versus-host disease as their primary indication, 2009
• Table: Late complications of hematopoietic stem cell transplantation
• Table: Selected drugs investigated in the treatment of steroid-refractory chronic graft-versus-host disease

FIGURES

• Figure: The normal hematopoiesis process
• Figure: Overview of the hematopoietic stem cell transplantation procedure
• Figure: The applications of autologous and allogeneic hematopoietic stem cell transplantation
• Figure: Main indications for hematopoietic stem cell transplantation in 2007, according to EBMT data
• Figure: Indications for allogeneic hematopoietic stem cell transplantation worldwide in 2005, according to CIBMTR data
• Figure: Annual number of hematopoietic stem cell transplantations worldwide, 1970 2006, according to CIBMTR data
• Figure: Stem cell sources for allogeneic and autologous transplants in patients over 20 years of age, 1997 2006, according to CIBMTR data
• Figure: The use of myeloablative and reduced-intensity conditioning regimens in allogeneic transplants, 1998 2006 according to CIBMTR data
• Figure: Age distribution of patients receiving allogeneic transplants by conditioning regimen intensity, 2005 06, according to CIBMTR data
• Figure: Causes of death after transplantations, 2001 06, according to CIBMTR data
• Figure: Unmet needs and research priorities in hematopoietic stem cell transplantation

相關商品

細胞療法相關市場調查報告書

神經幹細胞·前驅細胞產品的策略性開發

Strategic Development of Neural Stem & Progenitor Cell Products

價格 : US $ 3495

出版日期 : 2012年01月

細胞治療:技術˙市場˙企業

Cell Therapy - Technologies, Markets and Companies

價格 : US $ 5500

出版日期 : 2012年01月

個別化醫療：科學的・商業的情勢

Personalized Medicine - scientific & commercial aspects

價格 : US $ 5000

出版日期 : 2012年01月

Datamonitor發行的生物科技相關市場調查報告書

新的技術:幹細胞

Emerging Technologies: Stem cells

價格 : US $ 3800

出版日期 : 2011年11月

生技企業未來展望未來展望（至2016年）

Biotech Company Outlook to 2016

價格 : US $ 3800

出版日期 : 2011年11月

加拿大:學名藥和生技仿製藥概要

Canada: Generics and Biosimilars Overview

價格 : US $ 1900

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!